New tool could show how genetic variants raise Parkinson’s risk
A new screening method may shed light on the interactions between genetic variants that increase the risk of Parkinson’s…
Articles by Patricia Inácio, PhD
Study unveils mechanisms behind levodopa-induced dyskinesia
The motor cortex, a brain region responsible for movement control, becomes disconnected in levodopa-induced dyskinesia (LID), the uncontrolled movements that…
Serina raises $10M to develop SER-252 for advanced Parkinson’s
Serina Therapeutics has secured $10 million in new funding to support the development of its lead product, SER-252 (POZ-apomorphine),…
Fellowship awarded to study mobility in people with Parkinson’s
A fellowship worth more than $1.2 million will fund research focused on improving the mobility of individuals living with…
Targeting protein may limit toxic spread of alpha-synuclein in brain
Targeting a membrane protein called TMEM16F may help reduce the spread of toxic clumps, or aggregates, of alpha-synuclein — a…
Phase 2 trial of bezisterim in newly diagnosed patients to start soon
The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s…
Rights secured to distribute ablation system for damaged brain tissue
Zimmer Biomet announced that it has acquired select exclusive rights to distribute NeuroOne’s OneRF Ablation System, a…
Project in visual hallucinations in Parkinson’s awarded nearly $500K
A researcher at the University of Rhode Island has received nearly $500,000 in federal funding to investigate the neuronal changes…
Cerevance’s solengepras reduces off-time as levodopa add-on therapy
Adding Cerevance’s investigational oral therapy solengepras (CVN424) to standard Parkinson’s disease treatment significantly decreased off time, when…
Amprion raises $6M to develop test for Parkinson’s disease
Amprion said it has raised the initial $6 million of a $15 million financing deal that will help develop…